Altimmune Inc
Altimmune is a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for serious liver, metabolic, and cardiometabolic diseases. The company's lead investigational medicine pemvidutide is a balanced glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis and other metabolic disorders.
Focus areas at Altimmune Inc
The clinical trials section below shows all active and recruiting studies sponsored by Altimmune Inc, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Altimmune Inc is headquartered in Gaithersburg, United States, founded in 1997, publicly traded under the ticker symbol ALT. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Active Clinical Trials
FDA-Approved Drugs
Frequently Asked Questions About Altimmune Inc
Common questions about Altimmune Inc's rare disease programs, clinical trials, and treatments.